Mecbotamab vedotin is a monoclonal antibody conjugated commercialized by BioAtla, with a leading Phase II program in Liposarcoma. According to Globaldata, it is involved in 5 clinical trials, of which 4 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Mecbotamab vedotin’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Mecbotamab vedotin is expected to reach an annual total of $52 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Mecbotamab vedotin Overview
BA-3011 is under development for the treatment of solid tumors include non-small cell lung cancer (NSCLC), oral cancer, castration-resistant prostate cancer (CRPC), bladder cancer, breast cancer, fallopian tube cancer and peritoneal cancer, colorectal cancer, oral cancer, cervical cancer, ovarian cancer, head and neck cancer, liver cancer, lung cancer, melanoma, stomach cancer, pancreatic cancer, soft tissue sarcoma, osteosarcoma, bone sarcoma, Ewing sarcoma and endometrial cancer, chondrosarcoma, adenoid cystic carcinoma (ACC), renal cell carcinoma, mesothelioma of the pleura, leiomyosarcoma, synovial sarcoma, liposarcoma. The drug candidate acts by targeting AXL receptor tyrosine kinase. The drug candidate is developed based on conditionally active biologics (CAB) platforms.
BioAtla is a clinical-stage biopharmaceutical company that focused on on developing antibody-based therapeutics for the treatment of solid tumor cancer. The company product candidate includes BA3011, BA3021 and BA3071, BA3182, BA3142, BA3311, BA336 and BA3151. BioAtla lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is protein kinase receptor. Its BA3021 is developing a CAB antibody drug conjugate directed against receptor tyrosine kinase such as orphan receptor 2 (ROR2), BA3071 is therapeutic for multiple solid tumor indications, including renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer and cervical cancer. The company offers laboratories in the US and China. BioAtla is headquartered in San Diego, California, the US.
The company reported revenues of (US Dollars) US$0.3 million for the fiscal year ended December 2021 (FY2021), a decrease of 41.7% over FY2020. The operating loss of the company was US$95.8 million in FY2021, compared to an operating loss of US$33 million in FY2020. The net loss of the company was US$95.4 million in FY2021, compared to a net loss of US$35.9 million in FY2020.
For a complete picture of Mecbotamab vedotin’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.